Cells and tissues surrounding a breast cancer tumor may hold critical information about how patients will respond to ...

Estrogen-progestin hormone therapy used to manage menopausal symptoms and other women’s health conditions is associated with ...

In an effort to foster progress in cancer research, the National Institute of Standards and Technology (NIST) is releasing detailed and comprehensive data about the entire genetic content of a ...

The class-wise weight allocation to the base classifiers is one of the key features of the proposed algorithm. The presented framework surpasses all the existing methods currently employed on the ...

The American Medical Association has adopted a new policy aiming to help women reduce the risk of developing breast cancer.

HOUSTON, June 5, 2025 /PRNewswire/ -- On Wednesday, law firms Jeeves Mandel Law Group, P.C. and Milberg Coleman Bryson Phillips Grossman PLLC filed a class action lawsuit in federal court against ...

Ms. Moody explained her reasons for bringing a class action against Oscar. "By following my doctor's orders to have a diagnostic breast ultrasound, I did everything right. And still, Oscar made me ...

CLAIRITY BREAST analyzes subtle imaging features on screening mammograms that correlate with future breast cancer risk, making early risk prediction feasible based on a screening mammogram alone.

Bayer drug could ease side effects of common breast cancer treatment, detailed data show Elinzanetant appears to be an effective option for managing hot flashes and other disruptive symptoms ...

CLAIRITY BREAST provides clinicians with a first-in-class, novel platform for identifying future risk of breast cancer A milestone in equitable healthcare, with potentially life-saving insights from a ...

It is the first and only PROTAC ER degrader to be evaluated in a phase 3 clinical trial in breast cancer. PROTACs represent a novel class of therapeutic agents that harness the proteasome to ...

Two studies reveal promising treatments for breast cancer, enhancing options for patients with triple-negative breast cancer (TNBC) and estrogen receptor–positive tumors.